Oral GLP-1s (Lillys paltusotine-orforglipron, etc.) are expected in late 2025/2026, and might be covered differently (some plans treat orals less restrictively than injectables)
J., Linge, J
And big questions remain, starting with: Will these meds improve your health in the long run, and if so, how
Some people may need a slower taper, while others can move through the steps more quickly
Does the patch actually contain GLP-1 or Semaglutide
Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027